Lupus (Systemic Lupus Erythematosus) and cannabis in Texas
The state currently does not list this condition as qualifying, and the program does not provide open-ended physician discretion to add conditions. Verify with the state regulator, because programs change.
- ✗ No
- LEGAL
- Physician-prescribed lo…
- POSSESSION
- $0/yr
- STATE FEE
- 1–7 d
- TIMELINE
Texas statute and program
The Texas Compassionate Use Program (TCUP) is the operating authority for Texas patient certification. The authoritative legal text is: Texas Health & Safety Code Chapter 487: Compassionate-Use Program.
What the evidence says about cannabis and Lupus (Systemic Lupus Erythematosus)
Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease in which the immune system produces autoantibodies that attack the body's own tissues. Inflammation can affect joints, skin, kidneys, blood, lungs, heart, and the nervous system. Lupus is a relapsing-remitting disease — patients experience flares and periods of relative quiescence.
For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Lupus (Systemic Lupus Erythematosus) page.
How to qualify in Texas
The Texas Compassionate Use Program (TCUP) requires the following registration steps for a Lupus (Systemic Lupus Erythematosus) patient (or any qualifying diagnosis):
- See a TCUP-registered Texas physician. The Texas Compassionate Use Program (TCUP) operates as a physician-prescription model rather than a patient-card model. A Texas-licensed physician registered with the Compassionate Use Registry of Texas (CURT), with board certification in a relevant specialty for one of the qualifying conditions, must determine that the patient has a qualifying condition under Health & Safety Code Chapter 487 and prescribe low-THC cannabis (cannabis with ≤1% THC by weight).
- Prescription is entered into CURT. There is no separate patient registration step. The TCUP physician enters the prescription directly into the Compassionate Use Registry of Texas (CURT), which is administered by the Texas Department of Public Safety (DPS). The patient does not file a separate application, does not receive a state-issued medical cannabis card, and pays no state registration fee.
- No state patient fee. Texas does not charge a patient registration fee under TCUP because there is no patient registration; the prescription IS the access mechanism. The patient pays only the physician’s certification fee and the dispensing organization product cost. Caregivers are designated through CURT and pay no separate state fee.
- Pick up the prescription from a Texas dispensing organization. Texas has three licensed dispensing organizations under TCUP. The patient presents a Texas driver license or state ID matching the CURT prescription record to pick up low-THC cannabis products (oils, tinctures, gummies, lozenges, topicals — no flower, no inhalable vapor, no products over 1% THC by weight). Texas does not honor out-of-state medical cards; prescriptions are valid for renewal as determined by the TCUP physician.
- State registration fee
- $0
- Physician visit (typical)
- $200–$400
- Certification to card
- 1–7 days
- Out-of-state patients
- Not eligible
- Minors
- Eligible with caregiver
For full Texas registration steps, fees, and reciprocity rules, see the Texas cannabis-laws page.
ICD-10 code
A certifying physician documenting Lupus (Systemic Lupus Erythematosus) for the Texas medical cannabis program will typically record ICD-10 M32.9 or SNOMED-CT 55464009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.
Frequently asked questions
Does Texas list Lupus (Systemic Lupus Erythematosus) as a qualifying condition for medical cannabis?
No. Texas's qualifying-condition list does not currently include Lupus (Systemic Lupus Erythematosus), and the state's program does not give physicians open-ended discretion to add conditions outside the list. Patients with Lupus (Systemic Lupus Erythematosus) in Texas have limited in-state pathways under the medical program as written. Options to verify and pursue include: petitioning the state regulator to add the condition (where the statute permits public petitions); consulting a physician about whether a co-occurring listed condition could support certification; or reviewing whether the state's program is undergoing legislative expansion. Texas program rules change, so verify the current list with the regulator before drawing a final conclusion.
How do I get a Texas medical marijuana card for Lupus (Systemic Lupus Erythematosus)?
Because Texas does not currently list Lupus (Systemic Lupus Erythematosus) as a qualifying condition, a card for Lupus (Systemic Lupus Erythematosus) alone may not be obtainable in-state under the program rules as written. Step one is finding a physician licensed in Texas who is registered with Texas Compassionate Use Program (TCUP) and willing to evaluate Lupus (Systemic Lupus Erythematosus) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Texas does not honor out-of-state cards, so the certification process has to originate inside the state. The state minimum patient age is No statutory minimum; minors generally require a parent or legal guardian to act as caregiver. Confirm the current process with the state regulator before applying, because the rules change.
What does the evidence say about cannabis for Lupus (Systemic Lupus Erythematosus)?
For Lupus (Systemic Lupus Erythematosus), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Lupus (Systemic Lupus Erythematosus) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Lupus (Systemic Lupus Erythematosus) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Lupus (Systemic Lupus Erythematosus) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Lupus (Systemic Lupus Erythematosus); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.
Sources
- Texas Health & Safety Code Chapter 487: Compassionate-Use Programaccessed May 15, 2026
- NORML: Texas Laws & Penaltiesaccessed May 15, 2026
- Wikipedia: Cannabis in Texas (legislative history backlinks)accessed May 15, 2026
- TX Health & Safety Code §481.121: Possession of marijuanaaccessed May 17, 2026
- Texas Senate Bill 3 (2025): Hemp consumable products restrictionsaccessed May 17, 2026
- Texas Department of State Health Services: Compassionate Use Programaccessed May 17, 2026
- City of Austin Proposition A (May 2022) — cannabis cite-and-release ordinanceaccessed May 17, 2026
- NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases: Lupusaccessed May 18, 2026
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 18, 2026
“Substantial evidence that cannabis or cannabinoids are effective for chronic pain in adults.”
- Lupus Foundation of America: Marijuana and Lupusaccessed May 18, 2026
- American College of Rheumatology: 2023 Guideline for SLE Management (executive summary)accessed May 18, 2026
- MedlinePlus: Systemic lupus erythematosusaccessed May 18, 2026